| First Author | Ben-Crentsil NA | Year | 2024 |
| Journal | Cancer Discov | PubMed ID | 39189614 |
| Mgi Jnum | J:353813 | Mgi Id | MGI:7715039 |
| Doi | 10.1158/2159-8290.CD-24-0093 | Citation | Ben-Crentsil NA, et al. (2024) RNA shielding of P65 is required to potentiate oncogenic inflammation in TET2 mutated clonal hematopoiesis. Cancer Discov |
| abstractText | TET2 mutations (mTET2) are common genetic events in myeloid malignancies and clonal hematopoiesis (CH). These mutations arise in the founding clone and are implicated in many clinical sequelae associated with oncogenic feedforward inflammatory circuits. However, the direct downstream effector of mTET2 responsible for the potentiation of this inflammatory circuit is unknown. To address this, we performed scRNA and scATAC-seq in COVID-19 patients with and without TET2-mutated CH reasoning that the inflammation from COVID-19 may highlight critical downstream transcriptional targets of mTET2. Using this approach, we identified MALAT1, a therapeutically tractable lncRNA, as a central downstream effector of mTET2 that is both necessary and sufficient to induce the oncogenic pro-inflammatory features of mTET2 in vivo. We also elucidate the mechanism by which mTET2 upregulate MALAT1 and describe an interaction between MALAT1 and P65 which leads to RNA "shielding" from PP2A dephosphorylation thus preventing resolution of inflammatory signaling. |
